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In subjects with chronic hepatitis B (CHB), the lifetime risk 
of developing hepatocellular carcinoma (HCC) is estimated 
to be 25-37 times compared to non-infected subjects. The 
process of hepatocarcinogenesis is complex and involves 
well-documented host, viral, and environmental risk factors. 
The most important risks include host factors such as older 
age, male gender, the presence of cirrhosis, and viral factors 
such as the viral load, genotype, and the presence of basal 
core promoter mutations. To date, antiviral therapy is the 
only intervention demonstrated to significantly reduce 
the risk of HCC development in CHB patients. Although 
oxidative stress has been implicated in cancer development, 
there is no established benefit shown from treatment with 
antioxidizing agents such as silymarin, green tea, and 
vitamin E.
Recently, there has been emerging interest in the 
potential role of statins in the primary prevention of HCC 
in CHB patients. Beyond their well-established role in 
preventing cardio- and cerebro- vascular complications, the 
use of statins have also been associated with other beneficial 
effects including reducing the risk of cancer. However, the 
anti-neoplastic property of statins has not been consistently 
shown. In a population-based study from Denmark, there 
was no significant reduction in liver cancer with the use of 
statins, although a slightly reduced cancer incidence was 
observed (1). El-Serag et al., in a study analyzing 1,303 cases 
of patients taking statins with 5,212 matched controls, showed 
that statin use was associated with a significant reduction 
in HCC development among patients with diabetes (2). 
The adjusted odds ratio (OR) for any statin prescription was 
0.74 [95% confidence interval (CI), 0.64-0.87], although 
the effect was attenuated in a sub-analysis of patient without 
known liver diseases (OR 0.63). In another population-based 
case-control study from Taiwan, Chiu et al. examined 1,166 
liver cancer cases with an equal number of controls matched 
for age and sex (3). The adjusted OR was 0.62 (95% CI, 
0.42-0.91) for the group which had been prescribed statin 
at <215.4 defined daily dose (DDD) and 0.63 (95% CI, 
0.37-1.06) for the group with cumulative statin use ≥215.4 
DDD. Although the use of statin was associated with a 
reduced risk of liver cancer in this study, a dose-response 
relationship was not observed. The authors surmised that 
the numbers might have been too small to demonstrate a 
significant difference with various doses.
In a recent study published in the Journal of Clinical 
Oncology, Tsan et al. described a population-based cohort 
study from Taiwan of CHB patients, demonstrating that 
statin use may reduce the risk of HCC in patients infected 
with HBV in a dose-dependent manner (4). A total of 
33,413 CHB patients from the Taiwanese National Health 
Insurance research database were included in the cohort, 
of which 8.3% had used statins. There were 1,021 cases of 
HCC during the follow-up period, with an overall incidence 
rate of 310.4 cases per 100,000 person-years. The incidence 
rates of HCCs were 319.5, 260.5, 198.1, and 158.7 and the 
adjusted OR were 0.66 (95% CI, 0.44-0.99), 0.41 (95% CI, 
0.27-0.61) and 0.34 (95% CI, 0.18-0.67) for patients with 
statin use of 28 to 90, 91 to 265, and over 365 cumulative 
DDD respectively.
However,  even af ter  control l ing for  potent ia l 
confounders, using results extracted from a database not 
designed for this specific purpose has limitations. Powerful 
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predictors such as the presence of cirrhosis and the use of 
antiviral therapy were accounted for, but only within the 
limitations of their database. It is very likely that those with 
bridging fibrosis and early cirrhosis will not be identified 
in such a database, as the majority will be asymptomatic. 
Previous studies have shown the beneficial effect of 
antiviral therapy in reducing HCC risk in CHB (5,6), and 
profound and durable suppression of hepatitis B virus is 
likely to have greater effect in preventing HCC compared 
to statins. However, antiviral therapy is also reduced to a 
binary variable, without further analysis on the duration 
and efficacy of therapy. The duration of therapy and the 
virological response to antiviral therapy are likely to be 
more important factors than simple exposure to antiviral 
treatment. Important viral factors such as genotype, the 
presence of core promoter mutations, HBeAg status, 
and the level of HBV DNA also are not accounted for. 
Unfortunately these variables are unlikely to be available 
from such a database, and the authors appropriately adjusted 
for potential available cofounders such as age, sex, cirrhosis, 
diabetes, antiviral therapy, angiotensin converting enzyme 
inhibitors, and aspirin.
It is important to note that the authors allowed 2 years 
of follow-up to ensure adequate exposure before analysis of 
data. Theoretically, all HCC diagnosed within these 2 years 
should have been excluded. In the survival curve shown, 
this appears to be the case for the cohort stratified to those 
taking statin 28-90, 91-365, and >365 cumulative DDD. 
For those with a cumulative DDD <28, the incidence 
of HCC was also shown within the initial 2 years. One 
assumes that in the actual analysis, the lead-in of 2 years 
applied to all groups, that is, any HCC occurring within the 
first 2 years in the group with a cumulative DDD <28 were 
also discounted. If this was not performed, the question 
arises whether a significant difference will remain (as the 
incidence curve will shift towards the right), rendering the 
analysis invalid.
Despite the limitations mentioned above, Tsan et al. 
have demonstrated the potential benefit of statin in HCC 
reduction in CHB patients. The mechanisms by which 
statins can prevent HCC remain largely speculative. 
Possible mechanisms include interference of the mevalonate 
pathway, leading to reduction of its downstream products 
important in activation of various cellular proteins 
responsible for promoting apoptosis (7). Apart from 
inducing apoptosis, statins have also been shown to impair 
cell cycle progression, reduce cellular adhesion, modulate 
angiogenesis, and promoting growth inhibition (8-12). 
Particular to HBV, statins, through the inhibition of 
cholesterol synthesis and augmentation of oral antiviral 
therapy, may reduce HBV replication (13).
The evidence thus far provided by 3 large population 
studies demonstrates the potential chemo-protective effect 
of statins against HCC, and merits further attention. 
Whether statins can genuinely reduce the risk of HCC 
in CHB patients can only be answered by well-designed 
randomized controlled trials with sufficient power. If statins 
are definitively shown to reduce HCC in CHB patients, the 
paradigm may be reversed from statins being potentially 
hepatotoxic to their having beneficial effects for those with 
liver diseases.
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